Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-011 nasal spray in adults with moderate to severe seasonal allergic rhinitis
ChiCTR2500097674Phase 3Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pumecitinib in seasonal allergic rhinitis (SAR) (6 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Change from baseline in average retrospective Total Nasal Symptom Score over the 14-day treatment period. Started Feb 2025; status: recruiting.
02
Drugs
pumecitinib
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2500097674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097674.